MiRNA-93 in serum extracellular vesicles before and after low dose rate prostate brachytherapy

Koji Iinuma; Kyojiro Kawakami; Kosuke Mizutani; Yasunori Fujita; Takahiro Yamaguchi; Masaya Ito; Tomoyasu Kumano; Masayuki Matsuo; Masahiro Nakano; Takuya Koie; Masafumi Ito; Taku Kato

doi:10.21873/ANTICANRES.15016

MiRNA-93 in serum extracellular vesicles before and after low dose rate prostate brachytherapy

Koji Iinuma, Kyojiro Kawakami, Kosuke Mizutani, Yasunori Fujita, Takahiro Yamaguchi, Masaya Ito, Tomoyasu Kumano, Masayuki Matsuo, Masahiro Nakano, Takuya Koie, Masafumi Ito, Taku Kato

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background/Aim: To identify novel biomarkers for prostate cancer (PC), we evaluated changes of miRNAs contained in serum small extracellular vesicles (EVs) in patients who received low dose rate prostate brachytherapy (BT). Materials and Methods: EVs were isolated from the pooled serum of 10 PC patients prior to and 1 month after BT. miRNA profiling and quantitation in EVs was performed by microarray analysis and RT-digital PCR, respectively. Expression of miRNA-93 in prostate tissue was evaluated using the TCGA database and its level in EVs was determined in 25 patients before and 1, 3, 6 and 12 months after BT. Results: Profiling and quantitation identified miRNA-93 as significantly down-regulated in EVs after BT. TCGA database analysis showed that miRNA-93 was increased in PC tissue. miRNA-93 in EVs significantly decreased in 3, 6 and 12 months after BT. Conclusion: miRNA-93 contained in serum EVs may be a novel diagnostic and monitoring biomarker for PC.

Original language	English
Pages (from-to)	2411-2418
Number of pages	8
Journal	Anticancer research
Volume	41
Issue number	5
DOIs	https://doi.org/10.21873/ANTICANRES.15016
Publication status	Published - 05-2021
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/ANTICANRES.15016

Cite this

@article{0c271ada557a46d5b82e5567b8057dfa,

title = "MiRNA-93 in serum extracellular vesicles before and after low dose rate prostate brachytherapy",

abstract = "Background/Aim: To identify novel biomarkers for prostate cancer (PC), we evaluated changes of miRNAs contained in serum small extracellular vesicles (EVs) in patients who received low dose rate prostate brachytherapy (BT). Materials and Methods: EVs were isolated from the pooled serum of 10 PC patients prior to and 1 month after BT. miRNA profiling and quantitation in EVs was performed by microarray analysis and RT-digital PCR, respectively. Expression of miRNA-93 in prostate tissue was evaluated using the TCGA database and its level in EVs was determined in 25 patients before and 1, 3, 6 and 12 months after BT. Results: Profiling and quantitation identified miRNA-93 as significantly down-regulated in EVs after BT. TCGA database analysis showed that miRNA-93 was increased in PC tissue. miRNA-93 in EVs significantly decreased in 3, 6 and 12 months after BT. Conclusion: miRNA-93 contained in serum EVs may be a novel diagnostic and monitoring biomarker for PC.",

keywords = "Prostate cancer, extracellular vesicles, low dose rate prostate brachytherapy., microRNA-93, microarray analysis",

author = "Koji Iinuma and Kyojiro Kawakami and Kosuke Mizutani and Yasunori Fujita and Takahiro Yamaguchi and Masaya Ito and Tomoyasu Kumano and Masayuki Matsuo and Masahiro Nakano and Takuya Koie and Masafumi Ito and Taku Kato",

year = "2021",

month = may,

doi = "10.21873/ANTICANRES.15016",

language = "English",

volume = "41",

pages = "2411--2418",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "5",

}

TY - JOUR

T1 - MiRNA-93 in serum extracellular vesicles before and after low dose rate prostate brachytherapy

AU - Iinuma, Koji

AU - Kawakami, Kyojiro

AU - Mizutani, Kosuke

AU - Fujita, Yasunori

AU - Yamaguchi, Takahiro

AU - Ito, Masaya

AU - Kumano, Tomoyasu

AU - Matsuo, Masayuki

AU - Nakano, Masahiro

AU - Koie, Takuya

AU - Ito, Masafumi

AU - Kato, Taku

PY - 2021/5

Y1 - 2021/5

N2 - Background/Aim: To identify novel biomarkers for prostate cancer (PC), we evaluated changes of miRNAs contained in serum small extracellular vesicles (EVs) in patients who received low dose rate prostate brachytherapy (BT). Materials and Methods: EVs were isolated from the pooled serum of 10 PC patients prior to and 1 month after BT. miRNA profiling and quantitation in EVs was performed by microarray analysis and RT-digital PCR, respectively. Expression of miRNA-93 in prostate tissue was evaluated using the TCGA database and its level in EVs was determined in 25 patients before and 1, 3, 6 and 12 months after BT. Results: Profiling and quantitation identified miRNA-93 as significantly down-regulated in EVs after BT. TCGA database analysis showed that miRNA-93 was increased in PC tissue. miRNA-93 in EVs significantly decreased in 3, 6 and 12 months after BT. Conclusion: miRNA-93 contained in serum EVs may be a novel diagnostic and monitoring biomarker for PC.

AB - Background/Aim: To identify novel biomarkers for prostate cancer (PC), we evaluated changes of miRNAs contained in serum small extracellular vesicles (EVs) in patients who received low dose rate prostate brachytherapy (BT). Materials and Methods: EVs were isolated from the pooled serum of 10 PC patients prior to and 1 month after BT. miRNA profiling and quantitation in EVs was performed by microarray analysis and RT-digital PCR, respectively. Expression of miRNA-93 in prostate tissue was evaluated using the TCGA database and its level in EVs was determined in 25 patients before and 1, 3, 6 and 12 months after BT. Results: Profiling and quantitation identified miRNA-93 as significantly down-regulated in EVs after BT. TCGA database analysis showed that miRNA-93 was increased in PC tissue. miRNA-93 in EVs significantly decreased in 3, 6 and 12 months after BT. Conclusion: miRNA-93 contained in serum EVs may be a novel diagnostic and monitoring biomarker for PC.

KW - Prostate cancer

KW - extracellular vesicles

KW - low dose rate prostate brachytherapy.

KW - microRNA-93

KW - microarray analysis

UR - http://www.scopus.com/inward/record.url?scp=85105445920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105445920&partnerID=8YFLogxK

U2 - 10.21873/ANTICANRES.15016

DO - 10.21873/ANTICANRES.15016

M3 - Article

C2 - 33952466

AN - SCOPUS:85105445920

SN - 0250-7005

VL - 41

SP - 2411

EP - 2418

JO - Anticancer research

JF - Anticancer research

IS - 5

ER -

MiRNA-93 in serum extracellular vesicles before and after low dose rate prostate brachytherapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this